The issues that can complicate a CNS clinical trial often do not surface where teams initially expect them to.
Rather than appearing at database lock or during clinical study report (CSR) writing, they frequently begin much earlier within protocol assumptions, endpoint selections, or small omissions that may only gain importance later in the study.
By the time a CSR is drafted, some of those challenges may already be built into the trial. The real question is whether your CRO medical writing team is identifying potential risks early or working to explain them after the fact.
WHY CNS CLINICAL TRIALS ARE UNIQUELY COMPLEX TO DESIGN AND INTERPRET
Medical writing for CNS trials is fundamentally different from that of other therapeutic areas. Central nervous system studies are uniquely complex due to high and unpredictable placebo response rates, significant patient variability across neurological and psychiatric conditions, and heavy reliance on subjective clinical assessment scales.
For example, in neurodegenerative diseases, patients may require legally authorized representatives for consent. In psychiatric indications like depression or schizophrenia, placebo response and symptom fluctuations can create misleading outcomes. These factors can create a narrow margin for error within these types of clinical trials. Equally as important is the principle that emerges from long-term CNS experience; more is not always better. Adding more endpoints or assessments to a study can dilute statistical power, create logistical challenges, and overburden patients, ultimately increasing the risk for unusable data.
As a result, CNS trial design requires especially careful balancing and fine-tuning. Overdesigning a study can compromise data quality, while an underpowered study may yield inconclusive results.
That’s why CNS medical writing is not just that; it involves a certain strategic interpretation grounded in deep therapeutic expertise.
HOW 20 YEARS OF SPECIALIZED CNS MEDICAL WRITING SERVICES IMPROVE CLINICAL TRIAL OUTCOMES
At a CNS-focused CRO, medical writing is embedded in the study lifecycle, not isolated towards the end of a study.
Nurith Amitai-Crawford, Ph.D., CRC Senior Medical Writer, highlights that one of the biggest differences between Cognitive Research Corporation and larger, broader-focused CROs is the level of integration across teams. “Because our teams are deeply experienced in CNS research, our staff are able to contribute across multiple functions during a study,” says Dr. Amitai-Crawford. “That continuity creates a more cohesive experience for sponsors and helps ensure stronger alignment from protocol development through CSR completion.”
A specialized CNS environment allows for continuous cross-functional visibility. Medical writers are not just receiving outputs, they’re part of the ongoing dialogue with clinical teams, statisticians, and sponsors. This has led to a critical advantage for CRC: the ability to anticipate the trajectory of a study, informed by more than 20 years of highly specialized CNS experience.
With 20 years of CNS Research Experience the CRC Medical Writing Team Contributes to:
- Identifying study design risks early in protocol development
- Anticipating missing or inconsistent data scenarios
- Advising on assessment selection and study burden
- Flagging safety considerations specific to neurological and psychiatric populations
- Navigating operational realities like instrument licensing and patient compliance
HOW EARLY MEDICAL WRITING INSIGHTS PREVENTED RISK
In a recent study CRC has participated in, involving schizophrenia patients transitioning treatments, a suicide risk assessment (C-SSRS) had been removed from the protocol. At first glance, this might have been a standard protocol refinement. But based on her experience in psychiatric clinical trials, Dr. Nurith Amitai-Crawford recognized a critical issue: Schizophrenia patients already carry an elevated suicide risk, and in medication transition periods, that risk is further increased. She flagged the concern with the sponsor, and after revisiting the decision with an additional subject matter expert, they ultimately reinstated the assessment into the protocol based on Nurith’s advice. In doing so, they avoided regulatory concerns – such as a time-consuming FDA clinical hold – and prevented potential safety and data gaps for that study.
In another case, while preparing a clinical study report, Nurith already knew of a missing data discrepancy because she had been looped into earlier discussions between the statistics, management and sponsor teams. Instead of reacting late, she was able to integrate the correct scientific narrative immediately, ensuring the CSR accurately reflected the study’s context.
These moments illustrate a key reality: the value of medical writing in CNS trials comes from continuous engagement from the start, not last-minute interpretation.
3 QUESTIONS TO ASK CROs ABOUT THEIR CNS MEDICAL WRITING CAPABILITIES
When selecting a CRO for CNS clinical trials, sponsors should evaluate their medical writing capabilities with the same rigor as clinical or statistical functions.
WHEN DOES YOUR MEDICAL WRITING TEAM GET INVOLVED IN THE STUDY?
A strong CNS medical writing team should be involved well before CSR development begins. Early engagement helps writers understand the rationale behind protocol decisions, endpoint selection, assessment strategy, and potential operational challenges that could influence the interpretation of study data later. When medical writers are involved throughout the study lifecycle, they are often better positioned to identify inconsistencies, emerging risks, and data interpretation challenges as they develop rather than after database lock. This continuity can contribute to clearer scientific reporting and a more cohesive clinical narrative overall.
WHAT CNS-SPECIFIC EXPERIENCE DOES YOUR MEDICAL WRITING TEAM BRING?
CNS trials present unique challenges that require more than general clinical writing experience. Teams with dedicated CNS expertise are typically more familiar with issues such as placebo response, symptom variability, rating scale performance, patient heterogeneity, and the complexities associated with neuropsychiatric and neurological endpoints. That therapeutic understanding can play an important role in how study outcomes are contextualized, interpreted, and communicated in regulatory documents. Sponsors should also look for teams that understand the operational realities of CNS studies, including assessment variability across sites and the impact these factors can have on data interpretation.
HOW DO YOU BALANCE ASSESSMENT VOLUME WITH DATA QUALITY AND STATISTICAL POWER?
In CNS clinical trials, adding more assessments does not necessarily improve the quality or interpretability of the data. An excessive assessment burden can increase patient fatigue, complicate study logistics, introduce variability, contribute to incomplete datasets, and create challenges with site consistency. Experienced CNS teams recognize the importance of selecting relevant assessments while avoiding unnecessary complexity that may dilute detection of clinically meaningful effects or affect study execution. A thoughtful balance between assessment volume, data quality, and statistical considerations can help support more reliable outcomes and stronger overall study interpretability.
In CNS drug development, the difference between a successful study and an unusable one is often determined long before the final report is written.
The strongest medical writing teams in CNS don’t just document what happened, they anticipate what could go wrong, guide better decisions early, and ensure the scientific story holds together from protocol to CSR.
BUILT BY EXPERIENCE: THE VOICE BEHIND THE PERSPECTIVE
Nurith Amitai-Crawford, Ph.D., Senior Medical Writer
Dr. Amitai-Crawford has a Ph.D. in Neurosciences and 15+ years of scientific and medical writing experience in academic and industry settings. She has worked in all stages of the drug discovery and development process and has extensive experience authoring a wide range of scientific and regulatory documents, including clinical study reports (CSRs), clinical study protocols, Investigator’s Brochures, patient narratives, development safety update reports, investigational new drug applications (INDs), pre-IND briefing books, IND-enabling nonclinical study reports, and scientific journal articles. Prior to her medical writing career, Nurith worked in behavioral neuroscience research. Her hands-on experience gives her an in-depth understanding of CNS study design and data interpretation that informs and enriches her medical writing.
